The date for our Sahara Trek has changed!  AMEND's team, the Maniac Endocrine Nomads, who are raising money for AMEND's Research Fund, will now be starting their gruelling challenge from Friday 26th October, a week earlier than originally planned.  The 10-day trek will cover 100km of bush, scrub and spectacular desert sand dunes in sizzling temperatures, camping in tents each night.  The cost of the trip is now slightly less than previously, with a more flexible minimum fundraising target.  If you are interested in joining the team, time is of the essence as the organising company will shortly begin booking flights.  To sponsor our intrepid explorers, please visit our Maniac Endocrine Nomads page.  Good luck Maniacs!

An International, Randomised, Double-Blind, Two-Arm Study to Evaluate the Safety and Efficacy of Vandetanib 150 and 300mg/day in Patients with Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma with Progressive or Symptomatic Disease

10 Countries, 34 sites + 7 back-up sites
· US – 1 site (+ 1 back-up)
· Rest of the World – 33 sites (+ 6 back-up)

80 patients required, 14 months recruitment period expected

Inclusion Criteria of Interest
•Confirmed histological diagnosis of MTC
•Unresectable locally advanced and/or metastatic
•Hereditary or sporadic

•Objective disease progression within the previous 14 months, and/or
•Symptomatic

It is awaiting MREC and MHRA approval in the UK so recruitment should commence in June/July 2012.

If you think this trial may be of interest to you, please speak to your specialist.